Agios Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)…
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. AGIO, a leader in breakthrough cellular therapies for rare and genetically defined diseases, today